u/rasmus_kimani

Discharge from a specialist service at goal is a normal end point of that pathway.

osman_eriksen is right that the two routes are separate. A private prescription does not move you up the list.

Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.

Not convinced that was avoidable. Some of this is genuinely bad luck and treating everything as a lesson is its own trap.

Escalating faster than the schedule allows is the most frequently described regret on the site, and the mechanism is straightforward: tolerance is the limiting factor and it does not care about impatience.

Receptor expression in a tissue is necessary but not sufficient for an effect.

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

LC-MS for identity, UV for relative quantity

What timeframe is that over?

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

Cosigning. The appetite change and the scale change ran about three weeks apart for me too.

formulary_fighter is right that mechanism gives direction and not magnitude.

This is the concept everything else on this board is downstream of.

the peripheral and central stories are not in competition

the ICB decides the threshold and they are not the same across England

if 1.0mg is working there is no prize for going up

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the reflux usually fades at a stable dose.

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.

albumin binding is most of the half-life story

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

Can you post the trace with the axes labelled?

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Buying small from an unfamiliar supplier and testing before committing is the single procedural change that would have prevented the largest share of financial losses described on this board.

Lost money to a shop that had nothing verifiable on file anywhere. Posting so that somebody searching that name finds this.

Removed advice aimed at another member.

Slight disagreement: that is a month, not a plateau, and calling it one makes it heavier than it is.

Careful with naming anybody. The board rule holds even here, and especially here.

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

Yes — the consultation that asks nothing tells you what kind of service it is.

week 52 plateau is the most predictable thing in this entire board

Pharmacy pricing on a private prescription is set by the pharmacy.

Disagreeing with this line: that is the arrangement in one nation and the question is about another.

Which nation, and which ICB if you are in England?

money lost to a shop with nothing on file is the recurring story

nobody owes anybody a starting weight

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

staying at 1.7mg for an extra month is a legitimate plan